Company news
Xencor, Inc. news in 2022
Xencor, Inc.'s news releases, calls and decks from 2022, newest first.
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
December 11, 2022
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
November 9, 2022
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
November 6, 2022
Xencor Reports Third Quarter 2022 Financial Results
November 6, 2022
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
November 2, 2022
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
October 30, 2022
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
October 4, 2022
Xencor Appoints Nancy Valente, M.D., to Board of Directors
September 8, 2022
Xencor Reports Second Quarter 2022 Financial Results
August 2, 2022
Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
August 1, 2022
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
July 26, 2022
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
May 25, 2022
Xencor Reports First Quarter 2022 Financial Results
May 4, 2022
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
April 27, 2022
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 7, 2022
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 7, 2022
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
February 22, 2022
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
February 15, 2022
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
January 10, 2022
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 5, 2022
Calls in 2022
Decks in 2022
- Q3 2022 Earnings Presentation
Earnings · 23 slides · Nov 7, 2022